These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 35408778)

  • 1. Inhaled Placental Mesenchymal Stromal Cell Secretome from Two- and Three-Dimensional Cell Cultures Promotes Survival and Regeneration in Acute Lung Injury Model in Mice.
    Kudinov VA; Artyushev RI; Zurina IM; Zorina ES; Lapshin RD; Snopova LB; Mukhina IV; Saburina IN
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.
    Harrell CR; Jovicic BP; Djonov V; Volarevic V
    Anal Cell Pathol (Amst); 2020; 2020():1939768. PubMed ID: 33274176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives.
    Fernández-Francos S; Eiro N; González-Galiano N; Vizoso FJ
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
    Mattoli S; Schmidt M
    Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 6. Mesenchymal Stem Cells in the Treatment of COVID-19, a Promising Future.
    Beghini DG; Horita SI; Henriques-Pons A
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment.
    Aghayan HR; Salimian F; Abedini A; Fattah Ghazi S; Yunesian M; Alavi-Moghadam S; Makarem J; Majidzadeh-A K; Hatamkhani A; Moghri M; Danesh A; Haddad-Marandi MR; Sanati H; Abbasvandi F; Arjmand B; Azimi P; Ghavamzadeh A; Sarrami-Forooshani R
    Stem Cell Res Ther; 2022 Jul; 13(1):365. PubMed ID: 35902979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia.
    Hezam K; Mo R; Wang C; Liu Y; Li Z
    Curr Pharm Biotechnol; 2022; 23(9):1153-1167. PubMed ID: 34493193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent progress in mesenchymal stem cell-based therapy for acute lung injury.
    Liang J; Dai W; Xue S; Wu F; Cui E; Pan R
    Cell Tissue Bank; 2024 Jun; 25(2):677-684. PubMed ID: 38466563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease.
    Liu A; Zhang X; He H; Zhou L; Naito Y; Sugita S; Lee JW
    Expert Opin Biol Ther; 2020 Feb; 20(2):125-140. PubMed ID: 31701782
    [No Abstract]   [Full Text] [Related]  

  • 12. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
    Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
    Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19.
    Li JP; Wu KH; Chao WR; Lee YJ; Yang SF; Chao YH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyophilized powder of mesenchymal stem cell supernatant attenuates acute lung injury through the IL-6-p-STAT3-p63-JAG2 pathway.
    Peng W; Chang M; Wu Y; Zhu W; Tong L; Zhang G; Wang Q; Liu J; Zhu X; Cheng T; Li Y; Chen X; Weng D; Liu S; Zhang H; Su Y; Zhou J; Li H; Song Y
    Stem Cell Res Ther; 2021 Mar; 12(1):216. PubMed ID: 33781349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
    Gu J; Zhao Q; Han Z; Han Z
    Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
    Can A; Coskun H
    Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implications of mesenchymal stem cells in acute lung injury/acute respiratory distress syndrome.
    Wang YY; Li XZ; Wang LB
    Stem Cell Res Ther; 2013 May; 4(3):45. PubMed ID: 23673003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracellular vesicles in the pathogenesis and treatment of acute lung injury.
    Hu Q; Zhang S; Yang Y; Yao JQ; Tang WF; Lyon CJ; Hu TY; Wan MH
    Mil Med Res; 2022 Nov; 9(1):61. PubMed ID: 36316787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of mesenchymal stromal cell-derived therapies for acute respiratory distress syndrome-a meta-analysis of preclinical trials.
    Wang F; Fang B; Qiang X; Shao J; Zhou L
    Respir Res; 2020 Nov; 21(1):307. PubMed ID: 33218340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury.
    Vaka R; Khan S; Ye B; Risha Y; Parent S; Courtman D; Stewart DJ; Davis DR
    Stem Cell Res Ther; 2022 Jan; 13(1):20. PubMed ID: 35033181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.